Recent developments highlight Akebia's ongoing commercialization efforts for Vafseo, clinical trial progress, financial results reporting losses, and regulatory challenges including Nasdaq listing notice.

• Akebia reported third quarter 2026 financial results showing a net loss and revenue below expectations [N2][N4].
• The company held a Q3 2026 earnings call discussing commercial progress and clinical trial updates [N1][N3].
• Vafseo uptake is rising with increasing prescribing access and ongoing engagement with dialysis organizations [N8].
• Akebia received a Nasdaq minimum bid price deficiency notice in October 2026 [N5].
• The company continues clinical trials including the VOICE and VOCAL studies with topline data anticipated in late 2026 and early 2027 [N1][N3].
• Generic competition for Auryxia is present following loss of exclusivity in 2025, impacting revenue [N4].
• Akebia reported Q2 2026 losses and lagging revenue, consistent with recent quarterly trends [N6][N7].

Akebia has launched Vafseo, an oral anemia treatment for dialysis patients, with broad prescribing access and reimbursement secured, supporting its adoption. The company is advancing multiple mid-stage clinical programs targeting rare kidney diseases, including praliciguat and AKB-097, which expand its therapeutic portfolio. Ongoing clinical trials such as VOICE and VOCAL aim to generate additional data supporting Vafseo's efficacy and safety. The company's strategic focus on leveraging its kidney disease expertise and HIF biology capabilities supports pipeline expansion beyond kidney indications. A commercial infrastructure with key account managers detailing Vafseo supports market engagement. Financial resources include over $159 million in cash and equivalents as of September 2026, providing operational runway.

Akebia continues to incur significant losses and requires substantial additional financing, which may dilute existing shareholders or restrict operations. The company faces regulatory challenges, including discontinuation of the VALOR trial for non-dialysis anemia due to FDA feedback, and ongoing risks in obtaining approvals for pipeline candidates. Loss of exclusivity for Auryxia has introduced generic competition, adversely impacting revenue. The company received a Nasdaq minimum bid price deficiency notice, posing risks to listing status and capital access. Manufacturing complexities, reliance on third parties, and competitive pressures in the kidney disease market may hinder commercial success. Clinical trial enrollment difficulties and potential adverse safety or efficacy findings could delay or prevent product approvals.

Akebia's moat is anchored in its specialized focus on kidney disease therapeutics, with two FDA-approved commercial products addressing significant unmet needs in anemia and phosphate management in CKD patients. The company's oral treatment Vafseo offers a differentiated mechanism as the only oral HIF-based therapy approved in the U.S. for anemia in dialysis patients, supported by extensive clinical data and reimbursement arrangements facilitating adoption. Established commercial supply agreements with major dialysis organizations covering nearly all U.S. dialysis patients and embedded medical protocols enhance market penetration barriers. Additionally, Akebia's pipeline of mid- and early-stage rare kidney disease therapies and proprietary expertise in HIF biology contribute to its competitive positioning. However, the loss of exclusivity for Auryxia and potential generic competition pose challenges to sustaining revenue streams.

• Continued Losses and Financing Needs: Akebia has incurred significant losses since inception and anticipates ongoing losses, requiring substantial additional financing which may dilute shareholders or limit operations [S2].
• Nasdaq Listing Compliance: The company received a Nasdaq minimum bid price deficiency notice in October 2026, risking potential delisting and impacting stock price and capital access [N5].
• Generic Competition: Loss of exclusivity for Auryxia in March 2025 has led to authorized generic competition and potential additional generics entering the market, adversely affecting revenue [S1].
• Regulatory and Clinical Development Risks: Discontinuation of the VALOR trial for non-dialysis anemia due to FDA feedback indicates regulatory challenges. Clinical trials for pipeline candidates face enrollment, safety, and efficacy uncertainties [S1, S2].
• Dependence on Collaborations and Third Parties: The company relies on collaborations for development and commercialization and third parties for clinical trials and manufacturing, which may impact timelines and success [S2].
• Market and Competitive Risks: Competition from other therapies and companies may limit market share and product adoption. Changes in healthcare regulations and reimbursement could affect profitability [S2].
• Intellectual Property Risks: Limited or challenged intellectual property rights may reduce competitive advantage and expose the company to infringement claims [S2].

• Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on kidney disease therapeutics with two commercial products addressing complications of kidney disease [S1].
• The company markets Vafseo® (vadadustat), an oral HIF-PH inhibitor approved by the FDA in March 2024 for anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Vafseo entered the U.S. market in January 2025 with commercial supply agreements covering nearly 100% of dialysis patients [S1].
• Approximately 290,000 dialysis patients in the U.S. currently have prescribing access to Vafseo through protocols operationalized at dialysis organizations [S1].
• Vafseo is approved in 37 countries and marketed outside the U.S. by partners [S1].
• Auryxia® (ferric citrate) is an oral medicine approved and marketed in the U.S. for controlling serum phosphorus in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis-dependent CKD patients. Auryxia reached loss of exclusivity in March 2025, with generic competition anticipated in 2026 [S1].
• The company has a mid-stage rare kidney disease pipeline including praliciguat (licensed from Cyclerion) in Phase 2 for focal segmental glomerulosclerosis (FSGS) and AKB-097 (acquired from Q32 Bio) planned for a Phase 2 basket study in IgA Nephropathy, C3 Glomerulopathy, and Lupus Nephritis [S1].
• Early-stage pipeline assets include AKB-9090 (HIF molecule) planned for Phase 1 study in healthy volunteers targeting cardiac surgery-related acute kidney injury, and AKB-10108 in preclinical development for retinopathy of prematurity and other indications [S1].
• The company’s strategic imperatives include driving Vafseo to become the standard of care for anemia due to CKD in dialysis patients in the U.S., supporting Auryxia and advancing the rare kidney disease pipeline, and leveraging HIF biology expertise to expand beyond kidney disease [S1].
• Vafseo has reimbursement secured under the Transitional Drug Add-on Payment Adjustment (TDAPA) providing two years of additional payment to dialysis organizations starting January 2025 [S1].
• Dialysis organizations treating 82% of U.S. dialysis patients have commercial supply agreements for Vafseo, and medical protocols have been developed to enable prescribing [S1].
• Clinical trials ongoing include the VOICE trial (randomized 2,100 patients comparing Vafseo to epoetin alpha) with topline data anticipated in early 2027, and the VOCAL trial (post-marketing study in DaVita clinics) with topline data expected in late 2026 [S1].
• The company discontinued plans for the VALOR trial for anemia treatment in non-dialysis CKD patients due to FDA feedback indicating a larger, more costly trial would be required; discussions continue for smaller subpopulations [S1].
• Financial snapshot as of September 30, 2026: cash and equivalents $159.3M, current assets $220.8M, current liabilities $162.3M, net loss $14.35M for the quarter, basic and diluted EPS of -$0.05, current ratio 1.36, cash ratio 2.38 [S2].
• The company has incurred significant losses historically and anticipates continuing losses, requiring substantial additional financing [S2].
• Akebia received a Nasdaq minimum bid price deficiency notice in October 2026 [N5].
• Recent quarterly financial results show losses and revenue below expectations [N4, N6].
• Vafseo uptake is rising with increasing access and pipeline milestones approaching [N8].
• The company’s commercial team includes approximately 35 key account managers detailing Vafseo to prescribers [S1].
• The company relies on collaborations and third parties for development and commercialization of products and faces risks related to regulatory approvals, competition, intellectual property, and manufacturing complexities [S2].